Citation Impact
Citing Papers
Ror2 signaling regulates Golgi structure and transport through IFT20 for tumor invasiveness
2017 Standout
HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: Novel role of fumarate in regulation of HIF stability
2005 StandoutNobel
Loss of Hypoxia-Inducible Factor Prolyl Hydroxylase Activity in Cardiomyocytes Phenocopies Ischemic Cardiomyopathy
2010 StandoutNobel
Cluster of differentiation 8 and programmed cell death ligand 1 expression in triple-negative breast cancer combined with autosomal dominant polycystic kidney disease and tuberous sclerosis complex: a case report
2019
Lineage-Specific Changes in Biomarkers in Great Apes and Humans
2015 StandoutNobel
Inherited pancreatic endocrine tumor syndromes: Advances in molecular pathogenesis, diagnosis, management, and controversies
2008
Comprehensive Mutation Analysis of TSC1 and TSC2—and Phenotypic Correlations in 150 Families with Tuberous Sclerosis
1999
pVHL Acts as an Adaptor to Promote the Inhibitory Phosphorylation of the NF-κB Agonist Card9 by CK2
2007 StandoutNobel
Surgical management of brainstem hemangioblastomas in patients with von Hippel—Lindau disease
2003
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
2011 Standout
The Tuberous Sclerosis Complex
2006 Standout
Up-regulation of kidney NAD(P)H oxidase and calcineurin in SHR: Reversal by lifelong antioxidant supplementation
2003
Should We STOP Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Advanced Kidney Disease?
2016 Standout
The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer
2008 StandoutNobel
Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction
2004 Standout
Multiple Neuroendocrine Tumors of the Pancreas in von Hippel-Lindau Disease Patients
1998
Pheochromocytomas, Multiple Endocrine Neoplasia Type 2, and von Hippel-Lindau Disease
1993
Von hippel-lindau disease: New strategies in early detection and treatment
1994
Histopathology and Molecular Genetics of Multiple Cysts and Microcystic (Serous) Adenomas of the Pancreas in von Hippel-Lindau Patients
2000
Predictive Performance of Renal Function Equations for Patients with Chronic Kidney Disease and Normal Serum Creatinine Levels
2002
Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy
2001 Standout
Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex
2004 StandoutNobel
Molecular basis of the VHL hereditary cancer syndrome
2002 StandoutNobel
Phaeochromocytoma
2005 Standout
Hypoxia and Inflammation
2011 Standout
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
2003 Standout
Von Hippel‐Lindau disease
2003
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
2011 Standout
Mosaicism in Tuberous Sclerosis as a Potential Cause of the Failure of Molecular Diagnosis
1999
Nitric Oxide and Peroxynitrite in Health and Disease
2007 Standout
The NOX Family of ROS-Generating NADPH Oxidases: Physiology and Pathophysiology
2007 Standout
Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis
2008 Standout
Chronic kidney disease
2011 Standout
Assessing Kidney Function — Measured and Estimated Glomerular Filtration Rate
2006 Standout
Chronic Renal Failure after Transplantation of a Nonrenal Organ
2003 Standout
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
2003 Standout
Comparison of Risk Prediction Using the CKD-EPI Equation and the MDRD Study Equation for Estimated Glomerular Filtration Rate
2012
von Hippel-Lindau disease
2003 Standout
Endoplasmic Reticulum Stress and the Inflammatory Basis of Metabolic Disease
2010 Standout
Phosphorylation and Functional Inactivation of TSC2 by Erk
2005 Standout
Pheochromocytoma in Von Hippel-Lindau Disease
2003
Well-Differentiated Pancreatic Nonfunctioning Tumors/Carcinoma
2006
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
2013 Standout
Diabetes and Atherosclerosis
2002 Standout
VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400
2008 StandoutNobel
Tuberous sclerosis
2008 Standout
Renal function: the Cinderella of cardiovascular risk profile
2001
Pathogenesis of Tuberous Sclerosis Subependymal Giant Cell Astrocytomas: Biallelic Inactivation ofTSC1orTSC2Leads to mTOR Activation
2004
Pancreatic neuroendocrine tumors associated with von Hippel Lindau disease: Diagnostic and management recommendations
1998
Evidence That Lymphangiomyomatosis Is Caused by TSC2 Mutations: Chromosome 16p13 Loss of Heterozygosity in Angiomyolipomas and Lymph Nodes from Women with Lymphangiomyomatosis
1998
Pancreatic involvement in von Hippel–Lindau disease
2000
Tsc2+/– mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background
1999
Early-Onset Renal Cell Carcinoma as a Novel Extraparaganglial Component of SDHB-Associated Heritable Paraganglioma
2004
The natural history of hemangioblastomas of the central nervous system in patients with von Hippel—Lindau disease
2003
Mechanisms of angiogenesis
1997 StandoutNature
Relationship of renal function to homocysteine and lipoprotein(a) levels: The frequency of the combination of both risk factors in chronic renal impairment
2002
Age and Association of Kidney Measures With Mortality and End-stage Renal Disease
2012
Sporadic clear cell renal cell carcinoma but not the papillary type is characterized by severely reduced frequency of primary cilia
2008
Cystatin C versus Creatinine in Determining Risk Based on Kidney Function
2013
Tsc2 Null Murine Neuroepithelial Cells Are a Model for Human Tuber Giant Cells, and Show Activation of an mTOR Pathway
2002
Clinical and genetic analysis of patients with pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease
2000
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
2002 StandoutNobel
Surgical management of spinal cord hemangioblastomas in patients with von Hippel—Lindau disease
2003
A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells
2002
Moderate renal insufficiency and the risk of cardiovascular mortality: Results from the NHANES I
2002
Oxygen Sensing by Metazoans: The Central Role of the HIF Hydroxylase Pathway
2008 StandoutNobel
Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways
2005
Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization
2004 Standout
Chronic Kidney Disease
2016 Standout
Angiogenesis as a therapeutic target
2005 StandoutNature
Selective Inhibition of Hypoxia-Inducible Factor (HIF) Prolyl-Hydroxylase 1 Mediates Neuroprotection against Normoxic Oxidative Death via HIF- and CREB-Independent Pathways
2009 StandoutNobel
Pancreatic lesions in von Hippel–Lindau disease
2002
Central nervous system hemangioblastomas, endolymphatic sac tumors, and von Hippel-Lindau disease
2000
Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors
2003
Renal Function and Risk of Coronary Heart Disease in General Populations: New Prospective Study and Systematic Review
2007
RENAL LESION GROWTH IN CHILDREN WITH TUBEROUS SCLEROSIS COMPLEX
1998
Renal Insufficiency as a Predictor of Cardiovascular Outcomes and the Impact of Ramipril: The HOPE Randomized Trial
2001
Strategies for the Conversion of Lignin to High-Value Polymeric Materials: Review and Perspective
2015 Standout
THE RELATIONSHIP BETWEEN RENAL TUMOR SIZE AND METASTASES IN PATIENTS WITH VON HIPPEL-LINDAU DISEASE
2004
VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation.
2000
Luminescent Chemodosimeters for Bioimaging
2012 Standout
The Clinical and Pathological Manifestations of Renal Tumors in Von Hippel-Lindau Disease
1994
von Hippel-Lindau Disease
2006 StandoutNobel
Pathology, genetics and cell biology of hemangioblastomas.
1996
RENAL CANCER IN FAMILIES WITH HEREDITARY RENAL CANCER: PROSPECTIVE ANALYSIS OF A TUMOR SIZE THRESHOLD FOR RENAL PARENCHYMAL SPARING SURGERY
1999
Ferulic acid as a comonomer in the synthesis of a novel polymeric chain with biological properties
2009
Kinase requirements in human cells: III. Altered kinase requirements inVHL−/− cancer cells detected in a pilot synthetic lethal screen
2008 StandoutNobel
Pheochromocytoma
2002
pVHL 19 is a biologically active product of the von Hippel–Lindau gene arising from internal translation initiation
1998 StandoutNobel
Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.
1996 StandoutNobel
K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients
2005
Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas.
1995
Loss of function of the tuberous sclerosis 2 tumor suppressor gene results in embryonic lethality characterized by disrupted neuroepithelial growth and development
1998
Nephron Sparing Surgery for Renal Cell Carcinoma and von Hippel-Lindau’s Disease: A Single Center Experience
2003
Treatment of Intramedullary Hemangioblastomas, with Special Attention to von Hippel-Lindau Disease
2003
Fluorescent Chemosensors Based on Spiroring-Opening of Xanthenes and Related Derivatives
2011 Standout
Haemangioblastoma of the central nervous system in von Hippel–Lindau disease
1998
The von Hippel-Lindau Tumor Suppressor Protein and Egl-9-Type Proline Hydroxylases Regulate the Large Subunit of RNA Polymerase II in Response to Oxidative Stress
2008
The genetic basis of tuberous sclerosis
1998
Von Hippel-Lindau Syndrome
1999
Adrenal-sparing surgery for phaeochromocytoma
1999
Regulation of Hypoxia-Inducible mRNAs by the von Hippel-Lindau Tumor Suppressor Protein Requires Binding to Complexes Containing Elongins B/C and Cul2
1998 StandoutNobel
Surgical Management of Multi-Organ Visceral Tumors In Patients With Von Hippel-Lindau Disease: A Single Stage Approach
2003
Role ofVHLGene Mutation in Human Cancer
2004 StandoutNobel
Allelic deletion and mutation of the von Hippel-Lindau (VHL) tumor suppressor gene in pancreatic microcystic adenomas.
1997
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 Standout
Allelic loss is frequent in tuberous sclerosis kidney lesions but rare in brain lesions.
1996
Works of Peter Riegler being referenced
Oxidative stress and TGFb in kidney- transplanted patients with cyclosporin-induced hypertension. Effect of carvedilol and nifedipine
2002
Proteinuria and plasma total homocysteine levels in chronic renal disease patients with a normal range serum creatinine: critical impact of true glomerular filtration rate
2001
Apparent preferential loss of heterozygosity atTSC2 overTSC1 chromosomal region in tuberous sclerosis hamartomas
1996
Vitamin E-coated dialyzers reduce oxidative stress related proteins and markers in hemodialysis - a molecular biological approach
2004
Oxidative Stress in Kidney Transplant Patients With Calcineurin Inhibitor–Induced Hypertension: Effect of Ramipril
2002
A Tuberous Sclerosis Patient with a Large TSC2 and PKD1 Gene Deletion Shows Extrarenal Signs of Autosomal Dominant Polycystic Disease
1997
Pancreatic lesions in the von Hippel-Lindau syndrome
1991
A large TSC2 and PKD1 gene deletion is associated with renal and extrarenal signs of autosomal dominant polycystic kidney disease
1997
Lipoprotein(a) plasma concentrations after renal transplantation: a prospective evaluation after 4 years of follow-up
1999
Lipoprotein(a) Serum Concentrations and Apolipoprotein(a) Phenotypes in Mild and Moderate Renal Failure
2000
PREVALENCE, MORPHOLOGY AND BIOLOGY OF RENAL CELL CARCINOMA IN VON HIPPEL-LINDAU DISEASE COMPARED TO SPORADIC RENAL CELL CARCINOMA
1998
Central nervous system lesions in von Hippel-Lindau syndrome.
1992